Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related … Read More